source
- Sanofi halts development of Nurix's STAT6 degrader programSanofi announced it will stop work on an experimental drug that targets STAT6, a protein involved in immune signaling. The compound, known as SAR448272 and developed in partnership with Nurix, was…
- Novo says launch of obesity drug CagriSema in Europe delayed by a couple of yearsNovo Nordisk announced it will not bring its obesity candidate CagriSema to European markets for the next few years. The statement came from the company's outgoing chief financial officer, Karsten…